


Gastroschisis Clinical Pathway

University of California Fetal Care Consortium



Gastroschisis Clinical Pathway

University of California Fetal Care Consortium

Neonatologist Recommendations

Access and Other Care

1. For bedside silo placement / closure, recommend placing peripheral IV, pulse oximeter, nasal cannula (for respiratory distress if required), and orogastric tube (which should be suctioned manually during reduction of bowel)
2. Recommend peripherally inserted catheter (PICC) over central venous catheters (i.e., Broviac)
3. Recommend removal of central catheters as soon as 100kcal/kg/day of enteral feeds (or ad lib oral feeds) are achieved

Pain Control

1. Recommend oral sucrose water for bedside silo-placement, reduction, and closure
2. If narcotics are administered, limit to a single dose when feasible to help prevent apnea and intubation
3. Recommend the use of non-narcotic medications (e.g. acetaminophen)
4. Recommend discontinuation of narcotics ≤ 48 hours after abdominal closure

Antibiotics

1. The recommended prophylactic antibiotics for reduction and closure are ampicillin and gentamicin
2. Recommend discontinuation of antibiotics ≤ 48 hours after abdominal closure in the absence of culture-positive sepsis or clinical instability

Nutrition

1. Encourage oral care protocol with maternal breast milk at least 4x daily beginning first day of life
2. Recommend parenteral nutrition and IV lipids as soon as possible and no later than 24 hours of age.
 - Protein 2-2.5 g/kg/d
 - Lipids 1-2 g/kg/d
 - GIR 5-8
3. Recommend reaching goal parenteral nutrition by day of life 3 as tolerated
 - Protein: 3-3.5 g/kg term or 3.5-4 g/kg for late-preterm or younger
 - Lipid: 2-3 g/kg
 - Calories: 90-110 kcal/kg/d
4. Recommend early initiation of feeds (10-20 cc/kg/day) ≤ 48 hours after gastric output is non-bilious
5. Recommend oral feeds
6. Recommend use of breast milk or donor breast milk as a transition if maternal breast milk not available
 - Stop donor breast milk after reaching 60-100 cc/kg/d of feed
7. Recommend advancing feeds by ≥ 20 cc/kg/d as tolerated
8. Recommend not checking gastric residuals
9. Recommend minimizing pausing feeds unless clinical signs of intolerance
10. Growth parameters should be checked weekly. Changes in z-scores should be assessed
 - If a patient is demonstrating a decrease in weight or length z-score from birth that is greater than or equal to -0.8 after 14 days of life, recommend discussing increasing caloric goal

Routine intubation and paralysis are NOT recommended for bedside silo placement or reduction.

Gastroschisis Clinical Pathway

University of California Fetal Care Consortium

References:

1. Multi-institutional practice patterns and outcomes in uncomplicated gastroschisis: a report from the University of California Fetal Consortium (UCFC). Lusk LA, Brown EG, Overcash RT, Grogan TR, Keller RL, Kim JH, Poulain FR, Shew SB, Uy C, DeUgarte DA; University of California Fetal Consortium. J Pediatr Surg. 2014 Dec;49(12):1782-6. doi: 10.1016/j.jpedsurg.2014.09.018. Epub 2014 Nov 14.
2. Factors associated with gastroschisis outcomes. Overcash RT, DeUgarte DA, Stephenson ML, Gutkin RM, Norton ME, Parmar S, Porto M, Poulain FR, Schrimmer DB; University of California Fetal Consortium. Obstet Gynecol. 2014 Sep;124(3):551-7. doi: 10.1097/AOG.0000000000000425.

Specific Goals:

The recommendations for care in this pathway will be implemented with the following goals:

1. Standardization of care across University of California Medical Centers
2. Reduction in percentage of patients undergoing cesarean section delivery
3. Reduction in median length of stay (days)
4. Reduction in median ventilator days
5. Reduction in median antibiotic days
6. Reduction in narcotic usage
7. Reduction in days of parenteral nutrition
8. Reduction in days spent in silo
9. Reduction in overall cost
10. Increase in utilization of human milk

Gastroschisis Clinical Pathway Team:

Owner University of California Fetal Care Consortium

Medical Disclaimer:

The clinical pathways are based upon current, available evidence. The clinical pathways should not be used as medical advice. They should be used as a guide in managing patients. In addition to the clinical pathway, medical management is to be individualized, and may depend on medical resources available to the medical practitioners, the physician's clinical judgment and any special circumstances pertaining to the patient and/or family. They are not intended to establish a standard of care. Although the pathways are developed after careful deliberation, they cannot be guaranteed to be completely accurate or without omissions. UCLA is not responsible for any unexpected or adverse patient events or outcomes in connection with the application of the clinical pathways to patient management. Readers are encouraged to confirm the information contained within the clinical pathways with other references, sources and expert opinion prior to instituting a health care decision for patient care.